Dr. Jian Dong 董坚
Chief Physician
Medical Oncology (II), Yunnan Cancer Hospital, Kunming
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical focus on biological therapy for tumors.
Dr. Dong holds a master’s degree and serves as a chief physician. Research focuses on biological therapy for tumors.
Professional roles
- Member, Chinese Medical Association
Name order: in Chinese the family name comes first (Dong Jian). Papers usually list the name as Jian Dong or Dong J.
Selected publications
49 papers on PubMed matched by name and affiliation; 23 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Control Release, 2026 (senior author): Biomaterials-guided nanomedicine for familial adenomatous polyposis: lipid nanopartiscle RNA therapeutics with translational relevance. PubMed 41933803
- Front Genet, 2025 (senior author): A rare subtype of lynch syndrome familial with co-mutation of EpCAM c.344T>C, MSH2 c.2744A>G, PMS2 c.1408C>T and APC c.5465T>A, case report and literature review. PubMed 41164816
- J Transl Med, 2025 (senior author): Topical application of a placental mesenchymal stem cell-embedded biomaterial hydrogel accelerates the repair of radiation-induced skin damage: a double-blind randomized phase II clinical trial. PubMed 41053831
- Int J Biol Macromol, 2025 (senior author): C-Arg9-APCR3-VHL promotes β-catenin degradation via the VHL-mediated ubiquitin-proteasome system in APC-mutant colorectal cancer. PubMed 40782852
- Cancer Med, 2025 (senior author): Peripheral Blood T-Cell Receptor Repertoire Diversity as a Potential Biomarker in the Diagnosis and Treatment Evaluation of Colorectal and Lung Cancers: A Prospective Observational Study. PubMed 40387418
- Heliyon, 2024 (senior author): Whole transcriptome scanning and validation of negatively related genes in UC-MSCs. PubMed 38510024
- Curr Pharm Des, 2024 (senior author): Which Drugs are More Effective in Preventing Familial Adenomatous Polyposis Progression based on Network Meta-analysis?. PubMed 38698755
- BMC Cancer, 2022 (senior author): mir-145-5p is a suppressor of colorectal cancer at early stage, while promotes colorectal cancer metastasis at late stage through regulating AKT signaling evoked EMT-mediated anoikis. PubMed 36348305
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion